Evidence map›Paper›PMID 26757465›Full record

SynthesisJAMA2016

Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.

Navdeep Tangri, Morgan E Grams, Andrew S Levey, Josef Coresh, Lawrence J Appel, Brad C Astor, Gabriel Chodick, Allan J Collins, Ognjenka Djurdjev, C Raina Elley and 19 more

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readMeta-Analysis
In one paragraph

Synthesis in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 366 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
366citing papers in PubMed, 5 pooled it
33.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06274710 narecruitingnot on this mapstarted 2023, after this paper: background citation

Open Access Digital CommunitY Promoting Self-Care, Peer Support, and HEalth LitEracy (ODYSSEE) for Kidney Health (KH) Trial

TypeinterventionalSponsorUniversity Health Network, TorontoRan2023 to 2026Enrolled344ConditionsChronic Kidney DiseasesArmsODYSSEE-KH
NCT07098078 completednot on this map

Domperidone Dose and the Risk of Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol

TypeobservationalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2008 to 2024Enrolled15,000ConditionsChronic Kidney Disease (CKD)ArmsDomperidone (drug)
3 · Its place in the literature

Who cites it

366 citing papers in PubMed, 5 syntheses or guidelines pooled it, 673 citations in OpenAlex.

  1. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.Journal of the American Society of Nephrology : JASN · 2026
    Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

306 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 14 countries.

Navdeep TangriDepartment of Medicine, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Canada2Department of Community Health Sciences, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Canada.
Morgan E GramsJohns Hopkins Medical Institutions, Baltimore, Maryland.
Andrew S LeveyDivision of Nephrology at Tufts Medical Center, Boston, Massachusetts.
Josef CoreshJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Lawrence J AppelJohns Hopkins Medical Institutions, Baltimore, Maryland5Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Brad C AstorDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison7Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison.
Gabriel ChodickMedical Division, Maccabi Healthcare Services, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Allan J CollinsChronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota10Department of Medicine, University of Minnesota, Minneapolis.
Ognjenka DjurdjevDepartment of Measurement & Reporting, Provincial Health Service Authority, Vancouver, British Columbia, Canada.
C Raina ElleyDepartment of General Practice and Primary Health Care, School of Population Health, University of Auckland, Auckland, New Zealand.
Marie EvansDivision of Renal Medicine, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
Amit X GargDepartments of Medicine and Epidemiology and Biostatistics, Western University, and Institute for Clinical Evaluative Sciences, Ontario, Canada.
Stein I HallanDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science Technology, Trondheim16Division of Nephrology, Department of Medicine, St Olav University Hospital, Trondheim, Norway.
Lesley A InkerDivision of Nephrology at Tufts Medical Center, Boston, Massachusetts.
Sadayoshi ItoDivision of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
Sun Ha JeeDepartment of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.
Csaba P KovesdyMemphis Veterans Affairs Medical Center, Memphis, Tennessee20University of Tennessee Health Science Center, Memphis, Tennessee.
Florian KronenbergDepartment of Medical Genetics, Molecular and Clinical Pharmacology, Division of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.
Hiddo J Lambers HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands.
Angharad MarksDivision of Applied Health Sciences, University of Aberdeen, and NHS Grampian, Foresterhill, Aberdeen, Scotland.
Girish N NadkarniDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Sankar D NavaneethanDivision of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona.
Stephanie TitzeDepartment of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany.
Mark J SarnakDivision of Nephrology at Tufts Medical Center, Boston, Massachusetts.
Benedicte StengelCESP, INSERM, Villejuif, France29Université Paris-Saclay, Université Paris-Sud, UVSQ, Villejuif, France.
Mark WoodwardJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland30The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, England31The George Institute for Global Health, University of Sydney, Sy.
Kunitoshi IsekiDialysis Unit, University Hospital of the Ryukyus, Nishihara, Okinawa, Japan.
CKD Prognosis Consortium
Johns Hopkins University · USTufts Medical Center · USCleveland Clinic · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEIcahn School of Medicine at Mount Sinai · USInserm · FRKarolinska Institutet · SEKorea Health Promotion Institute · KRMemphis VA Medical Center · USNational Institutes of Health · USNHS Grampian · GBProvincial Health Services Authority · CASt Olav's University Hospital · NOTel Aviv University · ILThe George Institute for Global Health · AUTohoku University · JPUniversität Innsbruck · ATUniversity Medical Center Groningen · NLUniversity of Auckland · NZUniversity of Manitoba · CA

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI APPEL, LAWRENCE JOHN · 2001 to 2025
$15.7M
Proposal for a Chicago-CRIC Clinical CenterU01DK060980 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LASH, JAMES P. · 2001 to 2025
$15.4M
Tulane Clinical Center for Chronic Renal Insufficiency Cohort StudyU01DK060963 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI CHEN, JING, HAMM, L LEE · 2001 to 2025
$13.9M
Chronic Kidney Disease Prognosis Consortium (CKD-PC)R01DK100446 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, Morgan Erika Grams · 2014 to 2026
$10.7M
Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR001079NCI NIH HHS R01 CA165001NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100012CNIDDK NIH HHS K08 DK092287NIDDK NIH HHS K08DK092287NIDDK NIH HHS K23 DK002904NIDDK NIH HHS K23 DK067303NIDDK NIH HHS R01 DK100446NIDDK NIH HHS R01DK100446-01NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK035073NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

importanceIdentifying patients at risk of chronic kidney disease (CKD) progression may facilitate more optimal nephrology care. Kidney failure risk equations, including such factors as age, sex, estimated glomerular filtration rate, and calcium and phosphate concentrations, were previously developed and validated in 2 Canadian cohorts. Validation in other regions and in CKD populations not under the care of a nephrologist is needed.

objectiveTo evaluate the accuracy of the risk equations across different geographic regions and patient populations through individual participant data meta-analysis. DATA SOURCES: Thirty-one cohorts, including 721,357 participants with CKD stages 3 to 5 in more than 30 countries spanning 4 continents, were studied. These cohorts collected data from 1982 through 2014. STUDY SELECTION: Cohorts participating in the CKD Prognosis Consortium with data on end-stage renal disease. DATA EXTRACTION AND SYNTHESIS: Data were obtained and statistical analyses were performed between July 2012 and June 2015. Using the risk factors from the original risk equations, cohort-specific hazard ratios were estimated and combined using random-effects meta-analysis to form new pooled kidney failure risk equations. Original and pooled kidney failure risk equation performance was compared, and the need for regional calibration factors was assessed. MAIN OUTCOMES AND MEASURES: Kidney failure (treatment by dialysis or kidney transplant).

resultsDuring a median follow-up of 4 years of 721,357 participants with CKD, 23,829 cases kidney failure were observed. The original risk equations achieved excellent discrimination (ability to differentiate those who developed kidney failure from those who did not) across all cohorts (overall C statistic, 0.90; 95% CI, 0.89-0.92 at 2 years; C statistic at 5 years, 0.88; 95% CI, 0.86-0.90); discrimination in subgroups by age, race, and diabetes status was similar. There was no improvement with the pooled equations. Calibration (the difference between observed and predicted risk) was adequate in North American cohorts, but the original risk equations overestimated risk in some non-North American cohorts. Addition of a calibration factor that lowered the baseline risk by 32.9% at 2 years and 16.5% at 5 years improved the calibration in 12 of 15 and 10 of 13 non-North American cohorts at 2 and 5 years, respectively (P = .04 and P = .02). CONCLUSIONS AND RELEVANCE: Kidney failure risk equations developed in a Canadian population showed high discrimination and adequate calibration when validated in 31 multinational cohorts. However, in some regions the addition of a calibration factor may be necessary.

Indexed as

Proportional Hazards ModelsRisk AssessmentCohort StudiesDisease ProgressionHumansPrognosisRenal InsufficiencyRenal Insufficiency, Chronic

Identifiers

PMID26757465
PMCPMC4752167
OpenAlexW2234357320

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.